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Randomised trialAbstract Background: The use of chemotherapy to manage newly diagnosed low grade gli-
oma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus
four-drug regimens with a duration of 12 months of treatment after resection.
Methods: Within the European comprehensive treatment strategy for childhood LGG, the In-
ternational Society of Paediatric OncologyeLow Grade Glioma (SIOP LGG) Committee
launched a randomised trial involving 118 institutions and 11 countries to investigate the addi-
tion of etoposide (100 mg/m2, days 1, 2 & 3) to a four-course induction of vincristine (1.5 mg/
m2  10 wkly) and carboplatin (550 mg/m2 q 3 weekly) as part of 18-month continuing treat-
ment programme. Patients were recruited after imaging diagnosis, resection or biopsy with
progressive disease/symptoms. Some 497 newly diagnosed patients (M/F 231/266; median
age 4.26 years (interquartile range (IQR) 2.02e7.06)) were randomised to receive vincristine
carboplatin (VC) (nZ 249) or VC plus etoposide (VCE) during induction (nZ 248), stratified
by age and tumour site.
Findings: No differences between the two arms were found in term of survival and radiological
response. Response and non-progression rates at 24 weeks for VC and VCE, were 46% versus
41%, and 93% versus 91% respectively; 5-year Progression-Free Survival (PFS) and Overall
Survival (OS) were 46% (StDev 3.5) versus 45% (StDev 3.5) and 89% (StDev 2.1) versus
89% (StDev 2.1) respectively. Age and diencephalic syndrome are adverse clinical risk factors
for PFS and OS. 5-year OS for patients in early progression at week 24 were 46% (StDev 13.8)
and 49% (StDev 16.5) in the two arms, respectively.
Interpretation: The addition of etoposide to VC did not improve PFS or OS. High non-pro-
gression rates at 24 weeks justify retaining VC as standard first-line therapy. Infants with dien-
cephalic syndrome and early progression need new treatments to be tested. Future trials
should use neurological/visual and toxicity outcomes and be designed to discriminate between
the impact on disease outcomes of ‘duration of therapy’ and ‘age at stopping therapy’.
ª 2017 University of Nottingham. Published by Elsevier Ltd. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Childhood Low Grade Gliomas (LGGs) arise during
brain growth, developing in all areas of the central
nervous system (CNS). LGGs are predominantly of
grade 1 histology and are generally not anticipated to
undergo malignant transformation during childhood.
Resectability varies with location; hypothalamic-
chiasmatic tumours in particular are generally consid-
ered unresectable, they present when the children are
very young and can threaten vision, endocrine function
and require non-surgical therapy [1,2].
The SIOP Brain Tumour LGG Subcommittee had
developed a comprehensive, multimodality treatment
strategy for Childhood LGG, the International Society ofPaediatric OncologyeLow Grade Glioma (SIOP LGG)
committee, which was piloted and widely accepted clini-
cally [3,4]. Patients with progressive disease post-surgery
or disease threatening neurological function were
considered for non-surgical treatment.
Radiotherapy (RT) had previously been the mainstay
of treatment for incompletely resected LGG, butRT does
not confer a survival benefit or advantage in delaying first
progression [5,6]. Historically, the introduction of
chemotherapy in this disease groupwas aimed at delaying
or obviating the need for radiotherapy to minimise
cognitive, endocrine and vascular consequences [7e9]. A
variety of agents, given singularly and in combinations,
had been tried with a variety of indications in institution-
based trials, producing comparable results [1]. High
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70e90%) could be achieved, but 5-year PFS rates
declined after stopping treatments, especially in children
diagnosed who were less than 1 year of age [10].
The first SIOP LGG study was a multinational (UK,
Germany & Italy) single arm pilot study, launched to
test selection criteria for non-surgical treatments in
newly diagnosed patients with LGG. Non-surgical
therapy was stratified by age, those <5 years of age
were offered VC and those >5 years of age were rec-
ommended for radiotherapy.
The 12-month chemotherapy regimen of the first
SIOP LGG study comprised VC with an intensified 3-
month induction and a 9-month, reduced-intensity
continuing phase [3,4,11]. An analysis of risk factors
confirmed the improved outcome for patients with
neurofibromatosis type 1 (NF1)-associated visual
pathway glioma (NF1-VPG), whereas NF1-negative
patients had a higher risk for progression after stopping
chemotherapy.
In launching this trial, we intended to investigate
drug intensification in the non-NF1 group by adding
etoposide to the standard VC combination, driven by
reports of multiagent, Socie´te´ Franc¸aise d’Oncologie
Pe´diatrique (SFOP) regimens [12] and the ongoing
Children’s Oncology Group (COG 9952) randomised
trial comparing two drugs (VC) versus four drugs (thi-
oguanine, procarbazine, CCNU (lomustine), vincristine
[TPCV] regimen) [13]. In selecting etoposide we hoped
to harness its synergy with the platinum-derived agent
[14e20] and restrict its cumulative dose to control the
risk of secondary acute myeloid leukaemia (AML).
Treatment duration was extended to 18 months, on the
working hypothesis that childhood LGG is a chronic
disease process, driven by normal growth across child-
hood and therefore requiring therapy extended over
significant developmental periods. This is the first report
of the results of this randomised trial of chemotherapy
intensification in childhood LGG.
2. Study strategy and methods
2.1. Study strategy
The International Society of Paediatric OncologyeLow
Grade Glioma subcommittee (SIOP-LGG) 2004 study
was a multinational protocol for previously untreated
patients aged up to 16 years with the histological diag-
nosis of a LGG according to the World Health Orga-
nisation (WHO) classifications of 2000 and 2007. The
radiological diagnosis of an LGG was accepted for vi-
sual pathway glioma (VPG) in non-NF1 patients with
extensive visual pathway involvement and additional
hypodensity of the tumour on a native computed to-
mography (CT)-scan.
At diagnosis, best safe resection of the primary
tumour was recommended. Observation was scheduledfor all children who were without threatening clinical or
ophthalmological symptoms, while non-surgical ther-
apy was indicated at radiological progression following
diagnosis or at evidence of threatening symptoms [3,4].
Thus, patients were entered into the study at diagnosis
or after a period of observation (see Fig. 1).
Based on the concern of the side-effects of radio-
therapy at a younger age, the age split for chemo- versus
radiotherapy was chosen at 8 years within the SIOP-
LGG treatment strategy in 2004. Therefore, at the time
the study was launched, primary chemotherapy was
recommended for all children aged less than 8 years
where there was either progressive or symptomatic dis-
ease or threat to neurological functions such as loss of
vision. Older children could be included to receive
chemotherapy by local physician’s choice.
Within the chemotherapy arm of the study, non-NF1
patients with an LGG irrespective of histological subtype
or location, excluding isolated optic nerve tumours, were
eligible for the prospectively randomised trial to receive
either ‘standard’ VC or the ‘intensified regimen plus
etoposide’ (VCE) during the induction period. Eligibility
and exclusion criteria are detailed in Table 1. Random-
isation was stratified for age (<1, 1e8, and8 years) and
tumour location (pure chiasmatic/Dodge II, chiasmatic-
hypothalamic/Dodge III plus other supratentorial
midline structures, and tumours outside the supra-
tentorial midline). Randomisation was performed by a
centralised, interactive internet-based system that, after a
summary check of patient’s eligibility, generated the
random allocation using a randomised blocked design,
accounting for age and primary tumour site.
Standard induction consisted of ten weekly doses of
vincristine (VCR) 1.5 mg/m2 intravenous (i.v.) bolus and
four ‘single’ doses of carboplatin (CBDCA) 550 mg/m2
as 1-h i.v. infusion at 3-week intervals followed by three
cycles of simultaneous VC at 4-week intervals. Etopo-
side was added for intensification with 100 mg/m2 as 1-h
i.v. infusion on day 1e3 in weeks 1, 4, 7 and 10. For
consolidation, patients of both arms received ten 6-week
cycles of vincristine 1.5 mg/m2 i.v. day 1, 8 and 15 and
carboplatin 550 mg/m2 i.v. day 1. Total chemotherapy
treatment lasted 18 months, 6 months longer than the
pilot regimen from SIOP LGG [3,4].
Dose modification was advised for children <10 kg of
weight to carboplatin 18.3 mg/kg and vincristine
0.05 mg/kg. Further dose reductions of one-third were
recommended for children <6 months of age. Dose re-
ductions were prescribed in case of haematological or
organ toxicities. Hypersensitivity reaction to carbopla-
tin, where Common Toxicity Criteria (CTC) was grade I
(rash/mild fever), permitted the repeated administration
under close surveillance, premedication and slowed
infusion rate. Following CTC-grade II reactions,
replacement of carboplatin was recommended with cy-
cles of cis-platinum (30 mg/m2/3 h, day 1 and 2) and
cyclophosphamide (1500 mg/m2/1 h, day 1).
Fig. 1. Flow diagram of the study.
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quirements to start subsequent courses of chemotherapy
and supportive care. Concomitant medication for asso-
ciated or other conditions, not containing cytostatic
drugs, was permitted.
Radiological and clinical/ophthalmological response
assessment was scheduled at week 24, and repeated at
weeks 54, 85 and regularly thereafter.
Radiological response assessment followed accepted
criteria and was based on a 3-dimensional measurement
of the tumour size on the magnetic resonance imaging
(MRI) sequence on which the outline of the tumour was
best delineated. Volume calculation followed an
approximation to the formula of the rotational ellipsoid
((a  b  c)/2). Changes in tumour size were given in %
of the reference volume and categorised in progressive
disease (PD, >25% increase in volume or new lesion),
stable disease (SD, volume changes <25%), improvement
(IMP, 25e50% volume reduction), partial (PR, >50%
volume reduction) and complete response (disappearance
of all lesions). For the individual comparison the
respective sequence had to be the same at baseline and
follow-up, and if the best sequence changed also mea-
surements had to be repeated. Contrast enhancement
had no influence on staging. In non-measurable tumours
for whatever reason (very irregular or poor discrimina-
tion from surrounding normal brain) volume changeswere estimated, and changes were interpreted with
caution. The central review process evolved during the
trial with technical advances in transmitting scans.
Where it was carried out, the reviewers noted that the
treatment centres underestimated response, making it
unlikely that the response rates are an overestimate.
Assessment of ophthalmological function was
detailed in the protocol and response was graded as
‘better, same, worse’, as no internationally consented
response criteria had been available.
2.2. Statistical considerations
2.2.1. Material and methods
All trial patients who were randomised to be treated
with chemotherapy between 1st April 2004, and 14th
April 2014 and followed-up until 31st December 2014
are included. Patient data were reviewed and verified
between the national trial centres and the international
data centre. Reference pathological review was organ-
ised nationally, complemented by three international
panel meetings. Reference radiological review was also
organised nationally. Central radiological and histo-
logical review was recommended, but was not a pre-
requisite for this analysis.
The data bank was provided by CINECA (Casa-
lecchio, Italy). The Clinical Trial Unit of the Istituto
Table 1
Eligibility and exclusion criteria for the randomised part of the SIOP-
LGG 2004 trial.
Eligibility:
 Age: children and adolescents up to the completion of the 16th
year of life.
 Histology: Low grade glioma according to ICD-O Code
 Children with chiasmatic-hypothalamic tumours may be
eligible without histological diagnosis, if neuroradiologic
findings meet unequivocal criteria for the presence of a low
grade glioma.
 Primary tumour localisation intracranial and/or spinal cord.
 Disseminated low grade glioma
 Primary tumour diagnosis without pretreatment with chemo-
therapy or radiotherapy
 Informed consent given by the patient and/or his legal guardian
(parents)
Exclusion
 Associated genetic conditions like neurofibromatosis NF I or
tuberous sclerosis
 Primary diffuse intrinsic tumours of the pons, even if histolog-
ically astrocytoma I/II
 Low grade, but non-glial, rare intracranial neoplasms
 Pretreatment with chemo- or radiotherapy (except for steroids)
 Preexisting impairments of health status, making the conduct of
the study impossible or ethically unwise.
 Evidence of pregnancy or lactation period
Randomization: All eligible patients without Neurofibromatosis NF I
(receiving chemotherapy as their first non-surgical therapy) were
eligible for randomisation.
Participation in another clinical study: In case the patient participated
in another clinical study simultaneously to being enrolled in the study
SIOP-LGG 2004, which was not interfering with the present treatment
strategy (e.g. endocrinologic study), this should be known to the na-
tional study chairmen.
Medication: Concomitant medication for associated or other condi-
tions (e.g. hormone replacement, anticonvulsants), not containing
cytostatic drugs, should be recorded, but was no exclusion criteria.
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ment and descriptive analyses were performed, served as
International Data Centre. Survival analyses, including
the main question of the trial, were performed by the
Institute of Biostatistics and Clinical Research, Muen-
ster, Germany, which served as Statistical Trial Centre.
All statistical analyses were done on an intention-to-treat
basis and all protocol violations were analysed with their
randomised groups. A sensitivity analysis for the
confirmatory main question of the trial was performed
excluding two patients for whom reference pathology
revealed that eligibility criteria were not fulfilled (one
grade III astrocytoma after central review and one case
of Alexander disease). Continuous variables were sum-
marised as mean, standard deviation, quartiles, mini-
mum, and maximum values, and categorical variables
were reported as counts and percentages. Radiological
assessment of tumour response by MRI followed rec-
ommended criteria [21]. Clinical response was defined asclinical þ imaging non-progression. Considered positive
were complete response (CR), partial response (PR),
objective response (OR) and stable disease (SD). To
verify associations between response rate and treatment
randomisation arms, the chi-squared test was computed.
This study is registered with European Union Clinical
Trials Register No. 2005-005377-29.
2.2.2. Compliance with clinical strategy
The clinical strategy selecting patients for treatment or
observation had been extensively piloted [3,4]. Timing of
commencement of treatment after surgery, an observation
decision and randomisation was recorded. Dose intensity
compliance for chemotherapy drugs with chemotherapy
schedule was estimated proportionally, as was compliance
with drug hypersensitivity recommendations.
2.2.3. Survival analysis
Overall Survival (OS) was calculated from date of ran-
domisation until death of any cause or last contact for
patients alive. Progression-Free Survival (PFS) was
calculated from date of randomisation until an event,
defined as progression of residual tumour, relapse
following previous complete resection, appearance of new
or progression of existing metastasis, death of any cause,
or last contact for patients without event. To evaluate the
variable response at week 24, PFS (OS) was calculated
from date of response assessment until event (death) or
until last follow-up, if no event occurred. The distribution
of PFS and OS within each randomisation arm was
evaluated according to the KaplaneMeier method [22].
Cox regression models within the complete rando-
mised cohort were used to analyse the prognostic and
predictive values of clinical and biologic variables on OS
and PFS (See: Supplementary Methods).
Multivariable model building (See: Supplementary
Methods) included following variables: randomisation
arm, age at randomisation (categorical and continuous
with transformations: linear, square, cubic, logarithm),
gender, indication for treatment, extent of resection,
metastases status, tumour histology, primary tumour
site, localisation strata at randomisation, interval from
diagnosis to start of chemotherapy. To evaluate
response at week 24, further Cox regression models were
built with PFS/OS calculated from date of response
assessment while additionally including the variables
response status at week 24 and interval from random-
isation to response assessment.
Given for the final models are estimated hazard ratios
of the selected explanatory variables with their respective
95%confidence intervals and likelihood ratio test p-values.
2.3. Main question of the SIOP-LGG 2004 trial
The following confirmatory null hypothesis was tested:
The PFS of children on intensified induction does not
differ from the PFS of children on standard induction.
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test on difference on a significance level of 5% according
to the intention-to-treat principle using a 3-step adaptive
design based on the inverse normal method [23]. The
bounds of the adaptive design result from a 3-step group
sequential plan according to Pampallona and Tsiatis [24]
with futility stop, with DZ 0, two-sided significance level
5%, power Z 90% for hazard ratio (standard versus
intensified) 1.609, equidistantly spaced information rates
for the analyses, and equal allocation ratio to treatment
arms. The original group sequential design was advanced
to an adaptive design pursuant to a biostatistical
amendment (See: Supplementary Methods).
Besides the main question of the trial, all analyses
were regarded as exploratory and p values are given
descriptively to detect and study meaningful effects.
The analyses were carried out using SAS statistical
package (SAS, rel. 9.2; SAS Institute, Inc., Cary, NC)
and SPSS (version 23, SPSS Inc., Chicago, United States
of America).3. Results
3.1. Patient cohort
Between 1st April 2004 and 14th April 2012, 3417 pre-
viously untreated patients from 118 institutions in 11
countries were registered at the SIOP-LGG 2004 data-
base following the SIOP-LGG treatment strategy.
During the trial period, 1057 patients received chemo-
therapy. Of these, 497 non-NF1 patients were rando-
mised to receive either VC- (nZ 249) or VCE-induction
(n Z 248) (Fig. 2).
The demographic and clinical characteristics of the
two treatment groups of patients are summarised in
Table 2. They were balanced for age at diagnosis and
tumour location. Mean age was 4.3 (StDev 3.3) years at
diagnosis and 5.0 (StDev 3.7) years at randomisation. At
start of treatment, 14.7% were younger than 1 year,
66.0% with age 1 and <8 years, and 19.3% between 8
and 16 years. The sex ratio showed a slight male pre-
ponderance (1.15:1). Diencephalic syndrome (DS) was
defined as a secondary failure to thrive with proper
caloric intake, and no longitudinal growth impairment
was reported in 59 patients [2,25,26].
The majority of patients had partial resection or bi-
opsy only (76.2%) prior to the start of chemotherapy.
First surgery had been delayed for >3 months from
diagnostic MRI in 19 patients. Within the interval be-
tween diagnosis and start of chemotherapy, 106 patients
underwent up to four further tumour resections (1
nZ 84, 2 nZ 16, 3 nZ 5, 4 nZ 1). In the time period
between diagnosis and randomisation tumour progres-
sion, with or without associated symptoms, occurred in
six patients after initial total resection.The majority of histologies were pilocytic astrocy-
toma WHO Grade I (67.4%). Histological diagnosis was
local; additional central review was available for 54.5%.
Sixty-eight patients (13.7%) did not have verification
biopsy of the LGG, due to unequivocal neuroradiolog-
ical appearances.
There was a noticeable difference in the proportion of
patients with partial resection/biopsy (VCE > VC,
pZ 0.0218) and a minor difference in the proportion of
patients without biopsy (VC > VCE, p Z 0.0704).
Tumour dissemination at start of therapy was present
in 69 patients with comparable distribution of primary
tumour sites to the entire cohort. Disseminated lesions
were equally distributed throughout the intracranial and
spinal leptomeningeal space; extra-neural manifestation
was reported in five patients, all associated with the
presence of a ventriculoperitoneal shunt (VP-shunt).
Following stratification according to localisation and
age, primary chemotherapy after diagnosis was started
within 3 months for 60.2%, within 1 year for 80.9%, and
after more than 1 year for only 19.1%. The majority of
those with severe visual or neurological impairment,
including diencephalic syndrome (DS), started within
the first 3 months from the date of diagnosis.
3.2. Administration of treatment
Detailed treatment documentation was obtained for 242
patients receiving VC and 236 receiving VCE for a total
of 1574 and 1562 administered induction cycles respec-
tively (Table 3). Treatments administered and toxicity
were comparable in both arms over time. Compliance
with dose intensity targets for both vincristine and car-
boplatin were high (68e71.6%). The addition of etopo-
side did not alter this. Grade 4 haematological toxic
events were more common in VCE-arm and were asso-
ciated with more grade 3 infections. There was no dif-
ference in the actual duration of 21-week induction
treatment period between the two arms.
There were more interruptions to therapy in VC-
compared to VCE-arm although proportions of in-
terruptions due to tumour progression were similar,
69.7% versus 71% respectively. Four interruptions were
due to deaths, 1 in VC-arm and 3 in VCE-arm; three
were related to tumour progression, one a toxic death
relating to an infant with severe DS who died within
the 1st week of treatment from a Rotavirus sepsis that
pre-dated commencing therapy. The protocol specified
non-infectious status as a prerequisite for starting
chemotherapy.
Hypersensitivity reactions occurred in patients in both
arms, being less frequent in VCE (31/242 VC and 17/236
VCE). Most allergic events were managed according to
protocol recommendations (82%), with the consequences
listed in Table 3. During consolidation, the frequency of
hypersensitivity events continued to be lower in the group
in the VCE arm during induction (VC n Z 117, VCE
Fig. 2. CONSORT diagram.
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associated with no consequences, during induction in
53.7% (VC) and 72.2% (VCE), during consolidation in
35.1% (VC) and 33.8% (VCE). A switch of treatment torecommended alternatives occurred in 78/185 events in
117 patients (VC) and 24/71 events in 44 patients (VCE)
during the consolidation phase. This difference in hyper-
sensitivity rates between the two arms of the trial was an
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used after discontinuation of carboplatin therapy pre-
cluded us from trying to analyse the impact of hypersen-
sitivity on subsequent tumour responsiveness or toxicity.
3.3. Response assessment
Response assessment was scheduled at 24 weeks from
the start of treatment and performed after a median time
of 24.3 weeks for the evaluable patients on an intention-
to-treat basis. Comparing VC (n Z 211) and VCE
(n Z 210) using available scans, radiological response
comprised volume reduction respectively, in 46% versus
41%, stable disease (SD) in 46% versus 51% and pro-
gressive disease (PD) in 7% versus 9% (Table 3).
The study was designed to use PFS as primary end-
point. Clinical response/progression were allocated by
the treating physician. We checked information about
imaging and visual assessments. Compliance was vari-
able across national groups. Central radiological review
was performed for more than 50% of MRI controls
throughout the treatment phase. The proportion of
reviewed scans increased during the course of treatment,
as technical solutions for sharing scans improved in
national health systems in some countries.
Neurological improvement or stabilisation was re-
ported for three quarters of patients (VC 75.3%, VCE
77.8%), but we lack information as to whether this can
be attributed to treatment or to rehabilitation. An ac-
curate assessment of visual function and specifically of
visual acuity in response to treatment is available only in
a limited number of patients. Overall, ophthalmologic
response (predominantly visual acuity) for patients with
VPG was reported better/stable in 48/78 VC- (61.5%)
and 35/68 VCE-patients (51.5%), and deteriorated in 6/
78 (7.7%) versus 7/68 (10.3%). A more detailed analysis
of visual responses in national subgroup is in prepara-
tion for publication.
3.4. Outcome
After a median follow-up of 5.2 years, 430 children are
alive with or without evidence of disease (Table 4). Fifty-
four patients died (25 in the VC-arm, 29 in the VCE-arm),
the majority died of disease (n Z 43) or tumour-related
complications (nZ 9) including the toxic death after in-
duction in a case < 1 year with diencephalic syndrome
(DS) and Rotavirus sepsis. One death from second ma-
lignant neoplasm in theVCE-armwas reported (no details
documented). Only 30 patients in each arm are alive
without evidence of disease, while the majority are alive
with tumour. During the trial period, 263 events (PD or
death) were reported (133 VC versus 130 VCE): Pro-
gressive disease was judged by centre assessment by
combining radiological, visual and neurological re-
sponses. By the beginning of consolidation 67 events had
occurred (31 VC versus 36 VCE), 31 events occurredduring consolidation treatment (16 VC versus 15 VCE)
and 165 since the end of treatment (86VC versus 79VCE).
Details of radiotherapy were given for 59 patients.
They had attained a median age of 8.0 years, radiation
being delayed for median 2.3 years (range 0.7e4.3 years)
from diagnosis. While 54 children were treated at the
primary tumour site (41 external beam photons, 9
external beam, protons, 4 brachytherapy), 4 received
craniospinal irradiation, 1 not known. During the time
of the trial, it became clinical practice to use a variety of
salvage treatments including additional drug therapy
and repeat surgery before radiotherapy. Data describing
these other treatments was not collected, so radiation-
free survival cannot be calculated and given this change
in practice is unlikely to be a parameter in future trials
unless multiple strategies are defined at the outset.
3.5. Main question of the trial
After 66 events the first interim analysis was performed
with the decision to continue the trial to stage two. After
132 events the second interim analysis was performed
resulting in a futility stop (overall p Z 0.28). Conse-
quently, accrual to the trial was stopped on 15th April
2012 with non-rejection of the confirmatory null hy-
pothesis. A sensitivity analysis showed that the decision
on the futility stop does not depend on the two patients
with eligibility criteria not fulfilled.
3.6. Analysis of survival and prognostic factors
KaplaneMeier estimate for 5-year Overall Survival
(OS) is 89.2% (StDev 2.1) in the VC- and 88.8% (StDev
2.1) in the VCE-arm, and 5-year PFS is 46.1% (StDev
3.5) versus 45.3% (StDev 3.5), respectively, with a me-
dian time to progression of 4.1 years. All data are
summarised in Tables 5aed. (See Supplementary
Tables).
Univariable analyses for PFS by treatment-arm
(Table 5a) show no differences between VC and VCE
for the randomisation strata of tumour location but
indicate differences for the randomisation strata for age:
PFS is impaired for patients 8 years in the VCE-as
compared to the VC-arm. Radiological tumour
response at week 24, using Complete Response (CR)/
Partial Response (PR)/Objective Response (OR) versus
Stable Disease (SD) was not prognostic for PFS.
Following 18 months of chemotherapy, Progression-
Free Survival (PFS) is poorer in both arms for age
<1 year and dissemination at diagnosis, and when
diencephalic syndrome was the indication for treatment.
OS is poorer in both treatment arms for infants and for
those with early progression at week 24. Histological
subgroups differ for PFS and OS, but patients with
pilocytic astrocytoma have identical OS rates in both
arms. Differences observed between smaller subsets are
inconsistent, as were those for extent of resection.
Table 2
Patient characteristics.
Patients randomised All
(n Z 497)
VC
(n Z 249)
VCE
(n Z 248)
Gender (f/m) 231/266 118/131 113/135
Age at randomisation
Mean 4.98 4.96 5.01
Median 4.26 4.42 4.13
Median range (q1eq3) 2.02e7.06 1.99e7.06 2.14e7.07
Age group e strata at randomisation
<1 year 73 (14.7%) 38 35
1 and <8 years 328 (66.0%) 163 165
8 years 96 (19.3%) 48 48
Localisation e strata at randomisation
Supratentorial midline
Dodge II (chiasmatic) 47 (9.5%) 25 22
Dodge III and other
locations
268 (53.9%) 133 135
All other locations 182 (36.6%) 91 91
Primary tumour site
Cerebral hemispheres 32 (6.4%) 16 16
Supratentorial midline 315 (63.4%) 158 157
Dodge II 47 25 22
Dodge III 121 64 57
Others 147 69 78
Cerebellum 30 (6.0%) 16 14
Brainstem 80 (16.1%) 41 39
Spinal cord 40 (8.0%) 18 22
Extent of all surgeries prior to start of chemotherapy
Complete resection 6 (1.2%) 4 2
Subtotal/near total 32 (6.4%) 19 13
Partial resectiona 184 (37.0%) 85 99
Biopsy (open, stereotactic,
endoscopic)a
195 (39.2%) 94 101
Not evaluable 12 (2.4%) 6 6
No surgeryb 68 (13.7%) 41 27
Tumour histology/WHO grade
Pilocytic astrocytoma I 289 (67.4%) 141 148
Pilomyxoid astrocytoma II 36 (8.4%) 17 19
Diffuse glioma II 49 (11.2%) 25 24
Glioneuronal tumours I 30 (7.0%) 15 15
All others (LGG nos,
Astrocytoma nos, RGNT,
other mixed glioma)
25 (5.8%) 10 15
Dissemination prior to
treatmentc (M1/M2/M3/
M4/not known)
69 (13.9%)
(1/30/30/5/13)
27
(0/10/8/2/7)
42
(1/20/22/3/6)
Interval from diagnosis to start of chemotherapy
3.0 months 299 (60.2%) 148 151
3e6 months 49 (9.9%) 28 21
6e12 months 54 (10.9%) 27 27
12e24 months 51 (10.2%) 24 27
>24 months 44 (8.9%) 22 22
Indication to treatment (multiple recordings/patient possible)
Diencephalic syndrome 59 28 31
Severe/progressive
neurologic symptoms
218 107 111
Severe/progressive visual
impairment
183 85 98
Visual deterioration 119 55 64
Borderline vision 107 51 56
Nystagmus in infants 79 32 47
Loss of vision in second
eye with first eye blind
22 12 10
Pressure effect of tumour
mass
74 34 40
Symptomatic/progressive
metastases
20 6 14
Table 2 (continued )
Patients randomised All
(n Z 497)
VC
(n Z 249)
VCE
(n Z 248)
Radiological tumour
progression
198 99 99
Radiological progression
only
97 54 43
Radiological
progression
þ symptoms
101 45 56
a The proportions of partial resection þ biopsy are different between
the VC- and VCE-arm, p 0.0218.
b There is no significant difference between the proportions without
histological diagnosis, p 0.0704. Tumours were located in the VP 58,
other supratentorial midline structures 7, cerebellum 2, and caudal
brainstem 1.
c The proportions of dissemination between the VC- and VCE-arm
are different of borderline significance p 0.0495. Primaries were
located: 60.9% supratentorial midline, 13.0% brainstem, and 8.7% each
for cerebrum, cerebellum, and spinal cord.
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val to start of treatment were found to be predictive for
PFS (Table 5b and c). Taken together, these infer that
minor differences between treatment arms for factors
like extent of resection or histological subgroup are
rather by chance (Fig. 3).
Multivariable analysis (Table 5d) confirms the pres-
ence of DS, mostly present at young age, as an unfav-
ourable prognostic factor for PFS, relevant at date of
randomisation and beyond response assessment at week
24. The interaction of age and treatment group may be
seen from Fig. 4c in the observation that the
KaplaneMeier curves for VC and VCE in the age group
1e8 years overlap, whereas PFS in the age group >8 is
considerably worse in the VCE group as compared to
the VC group.
For OS, patient factors, including DS, age <1 year,
>8 years at randomisation were identified as unfav-
ourable. Diffuse gliomas grade 2 account for 11% of
biopsied tumours; they are the second commonest his-
tological subgroup after pilocytic astrocytoma. There
was a trend towards worse PFS on univariable analysis
but this trend was not identified as statistically notice-
able in multivariable analysis. When assessing OS
however diffuse glioma grade 2 histology did confer a
statistically noticeable adverse influence on survival
compared to pilocytic astrocytoma in multivariable
analysis with a hazard ratio of 5.56 (95% CI:
2.52e12.23). Of all factors, early tumour progression at
week 24 predicted for the most unfavourable OS with a
hazard ratio of 16.96 (95% CI: 8.21e35.07).
4. Discussion
This is the first European randomised trial of
chemotherapy in childhood LGG and only the second
worldwide. It has recruited patients after diagnosis using
standardised selection criteria for high risk or actual,
Table 3
Treatment details for the induction phase and response at 24 weeks
(intention-to-treat).
VC
(n Z 249)
VCE
(n Z 248)
Patients for analysis of treatment details 242 236
Number of administered cycles 1574 1562
Treatment duration to week 21 (median,
range, in weeks)
22.3
(10.0e36.0)
21.8
(20.0e28.8)
Actual mean dose intensity for patients
who completed induction (mg/m2/
week)
(n Z 206) (n Z 214)
Vincristine
Target 0.88 0.88
Actual (minemax) 0.6
(0.2e1.2)
0.6
(0.1e1.2)
Carboplatin
Target 175.0 175.0
Actual (minemax) 124.2
(35.5e290.9)
125.3
(25.0e361.7)
Etoposide
Target e 54.5
Actual (minemax) 39.7
(4.1e112.7)
Interruption of induction 33 21
Reasons for interruption
Progression 23 15
Death 1 3
Toxicity 3 1
Non-compliance 6 2
Change of diagnosis (delayed
pathological report)
1 e
Physician’s decision 4 1
Patient’s decision 1 1
Worst grade of toxicity (CTC-criteria)
CTC-grade 3 4 3 4
Haematological 45 159 26 188
Infection 44 2 73 1
Renal e e 1 e
Auditory/hearing e e 2 e
Nausea/vomiting 23 e 36 1
Constitutional symptoms 18 5 27 6
Neurology motor 16 2 17 e
Neurology sensory 12 1 13 1
Gastrointestinal 7 2 12 1
Hepatic 12 e 10 e
Carboplatin allergy
Patients with at least one allergic event 31 17
Number of allergic events 41 22
Treatment consequence per event
None (treatment continued) 22 16
Dose modified 4 1
Change to protocol alternative 8 2
Change after induction 1 e
Other 6 3
Response assessment at week 24 post induction (not included for
radiological response: interruption for progression 29,
death 4, no information available 43)
Interval (start of treatment to assessment)
Median (weeks, q1eq3) 24.4
(23.0e26.3)
24.1
(23.3e25.8)
Mean (weeks, minemax) 25.0
(12.8e76.0)
24.6
(12.0e36.1)
Standard deviation 4.89 2.72
Radiological response (n Z 211) (n Z 210)
CR 3 3
PR 59 50
Table 3 (continued )
VC
(n Z 249)
VCE
(n Z 248)
IMP 36 33
SD 98 106
PD 15 18
Ophthalmological response (vision) for
patients with visual pathway tumour
(n Z 78) (n Z 68)
Better 13 11
Stable 35 24
Worse 6 7
Not done/not applicable 24 26
Neurological response (n Z 215) (n Z 216)
Better 73 80
Stable (existing unchanged) 89 88
Worse (progression of existing or
emergence of new symptoms)
9 15
Not done/not applicable 44 33
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of a third drug to intensify treatment will improve
response rates and PFS, is not supported.4.1. Main question of the trial
The response rates in the two arms VC and VCE,
respectively, were 46% versus 41% for volume reduction
(CR, PR, OR), and non-progression rates were 93%
versus 91% at 24 weeks after the start of treatment. The
5-year PFS and OS survival rates for VC and VCE arm
were 46% and 45% (PFS) and 89% and 89% (OS).
Due to differences in eligibility criteria and treatment
details, comparison of our results to the only other
randomised trial in this disease (COG 9952) [13] is
difficult. Also the time-point of evaluating patient and
tumour status differed. Response rates in the COG trial
were assessed at the end of one year’s chemotherapy and
excluded those who had dropped out during treatment.
The non-progression rate in the COG 9952 at 1 year was
68% in both arms (CV: complete/partial 35%, minor
15%, stable disease 17%; TPCV: complete/partial 30%,
minor 22%, stable disease 16%). Their 5-year Event Free
Survival (EFS) was 39% for the CV- and 52% for the
TPCV-arm, and 5-year OS was 86% for CV and 87% for
TPCV. Their analysis identified significant sustained
EFS advantage for the TPCV drug regimen, using a
‘cure model’. Their EFS results bracket our 5-year PFS
results, whilst the OS results are similar.
For the CV arm in COG 9952 5-year EFS was 34%,
while 5-year PFS in SIOP-LGG 2004 was 46% for the
VC-arm. The two protocols differ with respect to length
of treatment and dosing scheduling of the drugs. In the
SIOP-LGG 2004, carboplatin (550 mg/m2) was given 3-
weekly in induction, 4-weekly in intensification phase
prior to week 24 and 6-weekly during continuation
phase for 12 months. In COG study, carboplatin
(175 mg/m2) was given weekly for induction over
10 weeks and during the continuation phase but at a
Table 4
Patient status.
All
(n Z 497)
VC
(n Z 249)
VCE
(n Z 248)
Current status
Alive, disease free 60 30 30
Alive, disease present,
regression
18 8 10
Alive, disease present,
stable
316 165 151
Alive, progression/relapse 36 16 20
Dead 54 25 29
No information/lost
to follow up
6/7 2/3 4/4
Reasons for death
Tumour progression 38 19 19
Metastases 5 2 3
Complications of tumour
or therapy
9 4 5
Relation to tumour
not clear
2 e 2
Radiotherapy (RT) for
progression
59 33 26
Median age at start of
RT (years, q1eq3)
8.0
(6.8e11.4)
7.8
(6.7e10.2)
8.7
(7.0e11.5)
Median time RT was
delayed (months, q1eq3)
27.4
(8.3e51.8)
30.5
(11.9e58.4)
15.9
(6.9e51.5)
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studies is the duration of therapy. Only a possible
prospective randomised trial could solve the issue, if the
difference in carboplatin scheduling and in the duration
of therapy could have some impact on EFS or PFS.
One of the reasons to prolong the 12-month vincristi-
neecarboplatin therapy of the SIOP-group had been
the convincing EFS of the original vincristine-carbo-
platin regimen, which lasted for 84 weeks [9,27]. But the
question of the ‘optimal’ duration of chemotherapy for
LGG has never been addressed properly until this
study.
The other significant difference between the two
studies is the choice of drugs in this patient group who
are very young and who have enhanced familial cancer
risk implicated by their tumour diagnosis [28]. The COG
4 drug arm (TPCV) includes three drugs with known
genotoxicity at significant cumulative doses (6 thio-
guanine, 640 mg/m2; procarbazine 1600 mg/m2; CCNU
880 mg/m2). The SIOP VCE arm specified etoposide at a
ceiling cumulative dose of 1200 mg/m2 in order to limit
exposure and the known risk of secondary AML. VC is
considered of low genotoxicity although carboplatin is
an alkylating agent. The histology of the one secondary
malignancy in the VCE-arm in this study could not be
retrieved. The higher 5-year EFS for TPCV in COG
9952 is of interest, however it did not translate to
improved OS. It is our understanding the TPCV is not in
routine use in USA despite the improved EFS rate.Concern about the risk of second malignancy may be a
factor.
Definitions of response have been standardised
internationally [21], and central review of radiologic
response assessment was organised nationally in our
trial. The impact of timing of response assessment has
not been investigated previously. Our choice of week 24
as main time point for response assessment was driven
by the concept of slow growing and thus slowly reacting
tumours. In this trial’s analysis, progression at week 24
proved to be the most important risk factor for death in
the multivariable model, OS being only 46% and 49%
for patients in PD at week 24 after both VC and VCE,
with a hazard ratio of 16.96. This risk factor has not
been reported previously.
The relevance of tumour response to chemotherapy
for the functional status has to be considered in
conjunction with the primary goal to defer radiotherapy.
While there were some reports on the improvement of
DS with chemotherapy [12,25], and the ophthalmologic
outcomes were better for responders in the French series
[12], no trial had assessed visual or neurological
outcome in detail [2,29,30]. Our trial reports clinical
improvement or stabilisation for the majority of our
patients following induction. The difficulties we
encountered in assessing visual response, particularly in
very young children, were linked to a lack of stand-
ardisation of visual and clinical measurements and weak
clinical contact with specialists in measurement of visual
function by trial participants, which impaired compli-
ance with reporting. Nevertheless, for the majority of
patients with visual pathway glioma early stabilisation/
improvement of vision, mainly visual acuity, was re-
ported. Single patient histories were rather heteroge-
neous, rendering it difficult to provide a comprehensive
statement regarding neurologic function in view of
interim surgery for hydrocephalus or tumour or second
and third line non-surgical treatments during long-term
follow-up.
Our patient cohort was recruited from 11 European
countries, all of them with a unique national health
system. Comparing the characteristics of this trial
cohort to the published series of Stokland et al. and
Gnekow et al. [3,4], which were fairly complete for their
countries, suggests that the large number of randomised
patients is representative.
4.2. Toxicity
Overall, there were more haematological toxic events
and infections reported in the VCE-arm, although
overall treatment time during the induction up to week
21 did not differ between the two arms. On the other
hand, fewer drug sensitivity reactions were reported in
the VCE-arm. The explanation for this latter significant
observation suggests an interaction between etoposide
Fig. 3. a: KaplaneMeier estimates and p-value of log-rank test for overall survival stratified according to randomisation arm (VC, VCE).
b: KaplaneMeier estimates and p-value of log-rank test for overall survival stratified according to age group (strata at randomisation:
<1 year, 1 and <8 years, 8 years) by randomisation arm (VC, VCE). c: KaplaneMeier estimates and p-value of log-rank test for
overall survival measured from response assessment in week 24 stratified according to response status at week 24: (1) Complete response
(CR), partial response (PR) or objective response (OR), (2) stable disease (SD), (3) progressive disease (PD). d: KaplaneMeier estimates
and p-value of log-rank test for overall survival stratified according to indication to start treatment (diencephalic syndrome (DS), other).
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sitivity. Management of hypersensitivity according to
protocol recommendations did not jeopardise inten-
tion-to-treat analysis. This unexpected finding could
not be further analysed for the interaction between
etoposide and hypersensitivity on progression risk
because of diverse treatment substitutions and varia-
tions in duration of ongoing therapy after carboplatin
discontinuation.Detailed reporting of toxicities revealed a significant
number of side-effects without differences between the
two chemotherapy arms. It cannot be differentiated
however, if they rather reflect the overall burden of
treatment or the general condition of the patients (e.g.
diencephalic syndrome). This relates specifically to
neurotoxicity (grade 3 and 4), which was reported dur-
ing induction for 18 VC- and 17 VCE-patients for motor
and for 13 VC- and 14-VCE-patients for sensory
A.K. Gnekow et al. / European Journal of Cancer 81 (2017) 206e225218impairment (Table 3). The reduced number of relevant
toxicities during consolidation most probably followed
the extended treatment intervals.
Thirty-eight patients interrupted induction or
consolidation therapy without progression or death, (10
during induction, 28 during consolidation). During in-
duction, four interruptions related to toxicity, and one
each for non-compliance, visual deterioration, neuro-
logical deterioration, physician’s and patient’s decision
and unknown. During consolidation ten incidents
interrupted for allergy, eight for toxicity, four due to
patient’s refusal/intolerance, three attributable to phy-
sician’s decision, three unknown. This significant pro-
portion of patients interrupting therapy emphasises the
importance of considering the tolerability of therapy,
particularly for those with non-progressive disease. Se-
lection of patients with the highest risk of progressive
disease will be important to justify the use of therapies
with significant risks of such toxicities in the future.
4.3. Patient tumour and treatment-related risk factors
4.3.1. Age
Early reports of chemotherapy in LGG had focussed
on younger children below 5 years, but had included
older patients. The COG 9952 trial set the upper age
limit at 10 years, whilst this study extended age range to
16 years [13]. The population based series and clinical
trials have all identified children younger than 1 year at
diagnosis at significantly higher risk for early progression
and death [3,4,13], especially if diagnosed at age below
6 months with diencephalic syndrome and/or tumour
dissemination [10]. A number of small institution-based
trials reported conflicting results with regard to the in-
fluence of age on response or progression [8,9,12,31]. Our
trial confirms a noticeably lower PFS and OS for infants
and children with diencephalic syndrome [2], which is
associated with large, centrally located tumours. The
majority of patients with progression at week 24 are from
this very young group with diencephalic syndrome.
This trial does identify an impaired PFS for the
greater than 8-year-old group in the VCE-arm, with a
lower OS for the older group in both arms. Both these
observations were unexpected. We had not intended to
randomise between VC and VCE in the entire larger
than 8-year age group as radiotherapy was originally
proposed as primary treatment for patients with pro-
gressive or symptomatic disease. Compliance with
treatment allocation across all centres has not been
specifically studied in this age group, nor has analysis of
anatomical or symptom subtypes being offered RT
versus chemotherapy. The numbers of patients from this
age group are relatively small with 48 (VC) and 48
(VCE) patients being drawn from the 8- to 16-year-old
age group compared to 163 (VC) and 165 (VCE) in the
main 1-<8-year age group and 38 (VC) and 35 (VCE) in
the <1-year group. Finally there is a greater proportion
of non-pilocytic tumours at non-visual pathwaysupratentorial midline locations in these arms, mirroring
age incidence patterns described by Stokland et al. [4]
Randomisation was not stratified for histology, but
non-pilocytic, i.e. diffuse astrocytoma does not predict
for PFS in this analysis.
For these reasons the difference between VC and VCE
regarding PFS in the older age group is of interest but
requires additional data and analysis to suggest an
interpretation. The observation of reduced OS in the
older age group similarly raises questions related to the
impact of tumours arising later in childhood. The pre-
vious COG study excluded children over 10 years [13].
Future studies will need to consider carefully, stratifica-
tion by age groups, obtain biological data about tumour
types and recording of pubertal status if the impact of
late childhood and adolescence on tumour behaviour
and sensitivity to treatment is to be better understood.
4.3.2. Dissemination
Primary dissemination of LGG has been described to be
an unfavourable prognostic factor [32,33], confirmed by
this report with an impaired PFS. The impact of
dissemination is statistically noticeable, suggesting that
patients with disseminated tumours experience pro-
gression more frequently even following non-
progression at response assessment at week 24.
4.3.3. Tumour site
Our randomised cohort was stratified for tumour loca-
tion, assuming a favourable prognosis for smaller visual
pathway tumours, primarily involving the chiasm,
rather than the more extensive chiasmatic-hypothalamic
tumours and other supratentorial midline locations [2].
We could not identify tumour site as a prognostic factor
for PFS or OS, in contrast to the unfavourable prog-
nosis for thalamic tumours in the COG trial [13]. The
issue of the potential role of tumour dimension in pre-
dicting response to therapy and more importantly ulti-
mate patients’ outcome still remains an open question.
4.3.4. Histology
The impact of the different low grade histologies on
response to chemotherapy, PFS and OS has not been
systematically investigated in the past. Pilocytic astro-
cytoma is the majority group in all trials. Clinically
diagnosed patients without biopsy are also included in
previous reports, particularly where tumours involve
visual pathways and hypothalamus. A trend for a higher
progression rate was reported for fibrillary/diffuse as-
trocytoma in the COG 9952 trial [13], but was not
confirmed in this multivariable analysis. The analysis of
Stokland identified that fibrillary/diffuse astrocytoma
had a significantly lower PFS rate, the cohort included
treated and untreated as well as NF1 and non-NF1
patients [4]. In this study, histological subtype did not
predict PFS but is a relevant prognostic factor for OS.
We conclude that patients with diffuse glioma WHO
Fig. 4. Full legend can be found on the next page.
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offered further treatment, if they progress after chemo-
therapy. Glioneuronal and pilocytic histology had the
most favourable OS; the other groups including imag-
ing-diagnosed patients had inferior OS. Emerging
knowledge of histological and molecular genetic sub-
grouping will be explored in future trials.
4.3.5. Surgery
In the COG 9952 study, patients were eligible and
started chemotherapy, if they were newly diagnosed with
less than 95% resection or had residual tumour >1.5 cm2
(72% of patients) or had progression after surgery (27%
of patients) (unknown 1%) [13]. In our trial, the presence
of a postoperative residual was no indication to
chemotherapy on its own. Patients also had to have
severe tumour-related symptoms or tumour progression.
More than 60% of patients started treatment within
3 months of diagnosis. Those starting treatment
following a phase of observation had pure radiological
progression in 19.5%, while the others had symptomatic
plus radiological progression. The actual tumour
dimension at the time of starting therapy was not
consistently recorded particularly for visual pathway or
hypothalamic-chiasmatic glioma in the present study.
Thus the impact of tumour dimension on tumour
response and PFS could not be reliably studied. The
extent of initial tumour resection was not an indepen-
dent prognostic risk factor at multivariable analysis.
Residual disease alone, in our view, is not an indication
for non-surgical therapy.
4.3.6. Chemotherapy
With only few formal phase II studies, the introduction
and use of chemotherapy for LGG largely based upon
results from small patient series, including regimens with
vincristine, actinomycin D, cyclophosphamide, cis- or
carboplatin, procarbazine, CCNU, thioguanine,
etoposide or vinblastine [8,9,14e20,27,34e36]. As well,
a small series investigated the combination of bev-
acizumab and irinotecan, vinorelbine or temozolomide
[37e42]. Efficacy was judged by assessing radiological
tumour response, while survival (OS) and progression-
free survival (PFS) data were not always available. All
drug combinations produce comparable ‘response rates’
without offering any better efficacy over others. AFig. 4: a: KaplaneMeier estimates and p-value of log-rank test for progr
VCE). b: KaplaneMeier estimates and p-value of log-rank test for pr
randomisation: (i) Pure chiasmatic/Dodge II, (ii) chiasmatic-hypothalam
supratentorial midline. SM: Supratentorial midline. c: KaplaneMeier
stratified according to age group (strata at randomisation:<1 year,1 a
patients without event by the time of response assessment at week 24: Ka
free survival measured from response assessment in week 24 stratified a
partial response (PR) or objective response (OR), (ii) stable disease (
progression-free survival stratified according to indication to start treatcomparative analysis of the respective toxicities is
hampered by the heterogeneous use of drugs or combi-
nations as first line or salvage treatments. Despite a
large number of publications, only 23 articles on the use
of CT for visual pathway glioma met the inclusion
criteria for a systematic research in 2006 [30]. Yet,
except for two, most cohorts were neither well-defined
nor representative or lacked complete follow-up, and
thus did not allow analysis of prognostic risk factors.
Within the last 30 years only two prospective rando-
mised trials systematically investigated chemotherapy
[13], one being this report.
Following the identification of mutations within
genes for the MAPKinase pathway a major signalling
pathways within LGG [43e45], tumour biology needs to
be assessed by integrating molecular and histological
factors, as well as clinical criteria for prognostic impact
to be established in prospective clinical trials. Future
randomised trials should continue to be stratified by
non-NF1 and NF1-associated cases and to examine the
impact of the current ‘standard’ drug regimen with new
targeted therapies and their effects on tumour response
and functional outcomes and toxicities. A revised set of
internationally standardised eligibility criteria, response
definitions and procedures are in development for the
next generation of trials which will include ophthalmo-
logic, neurological and QoL outcomes as primary
outcome measures in addition to the standard PFS and
OS. Their design will permit serial drug testing as new
treatments emerge.
5. Conclusions
We conclude that the good early non-progression rates
measured at 6 months in newly diagnosed cases justify
retaining VC as the standard arm for future phase III
trials seeking to explore the use of new first line treat-
ments with less toxicity. The new MAPKinase pathway
targeted drugs becoming available offer the opportunity
to be tested as part of either primary therapy random-
isation in newly diagnosed cases or in patients who are
progressing during, or at the end of induction. Trials
should be designed to discriminate between the impact
of ‘duration of therapy’ and ‘age at stopping therapy’ as
being factors that may determine progression risk.
Those presenting in the 1st year of life with diencephalicession-free survival stratified according to randomisation arm (VC,
ogression-free survival stratified according to localisation strata at
ic/Dodge III plus other midline structures, (iii) tumours outside the
estimates and p-value of log-rank test for progression-free survival
nd<8 years,8 years) by randomisation arm (VC, VCE). d: For all
planeMeier estimates and p-value of log-rank test for progression-
ccording to response status at week 24: (i) Complete response (CR),
SD). e: KaplaneMeier estimates and p-value of log-rank test for
ment (diencephalic syndrome (DS), other).
Research in context
Evidence before this study
Childhood low grade glioma are predominantly pilocytic grade 1 tumours with a small proportion of grade 2 tumours and
other rare entities, a proportion are diagnosed without biopsy on imaging characteristics. Together they represent 40% of all
childhood brain tumours and are the commonest solid tumour of childhood requiring active management. A small pro-
portion of these non-malignant tumours is thought to eventually transform to more malignant phenotype in adulthood.
Currently there are no established predictive factors for this risk. Most are sporadic, arising within a single location including
hypothalamus, chiasm, optic nerves, cerebellum, cerebral cortex, brainstem and spinal cord, with primary and secondary
dissemination in 5e10%. About 15% are associated with neurofibromatosis type 1 (NF1), with a majority of tumours
affecting the visual pathways, many being multifocal, but also involving brainstem and cerebellum. In NF1, surveillance
programmes of visual function are in place to identify children with visual changes justifying brain imaging. Sporadic tu-
mours, on the other hand, present clinically throughout childhood although there are classical age distributions associated
with different anatomical locations i.e. hypothalamic chiasmatic tumours most commonly present in the first 2 years of life,
the younger the patient the larger the tumour. Cerebellar tumours can occur throughout childhood. Cortical tumours tend to
occur in later childhood, as do brainstem and spinal tumours.
Multidisciplinary strategy: Previous multicentre pilot study had tested the applicability and acceptability of a multidisci-
plinary treatment selection versus observation strategy across Europe and found high clinical compliance. Furthermore,
patient, genetic, symptom, anatomical and tumour factors had been identified as stratifying factors for treatment selection.
Treatment: Historically treatment has relied upon primary resection, where clinically feasible, without neurotoxicity. Where
not feasible and if progressive, radiotherapy was used leading in many cases to severe neurotoxicity affecting the child’s
subsequent growth, endocrine and cognitive development and risk of second tumours. In the 1980s chemotherapy was re-
ported to successfully control tumour progression in very young children with progressive, unresectable tumours. Vincristine
and actinomycin D were used initially. We had conducted a prolonged international pilot study investigating the role of
vincristine carboplatin combination in carefully selected patients which has been reported in two publications studying the
impact of selection criteria on progression risk and the interaction between patient and treatment factors on progression free
and overall survival.
At the time of launching this trial we knew:
 We would expect high overall survival rates (>85% 5-year OS) (children under 1 year of age at diagnosis with diencephalic
syndrome and hypothalamic tumours having the poorest overall survival);
 over 60% of LGGs were pilocytic astrocytoma;
 grade 2 diffuse astrocytoma had poorer progression-free survival;
 Visual pathway glioma and other LGGs associated with NF1 had a favourable prognosis for progression-free and overall
survival. In view of their cancer predisposition they should be studied separately;
 genetic biomarkers of LGGs have not been identified.
 radiotherapy had been used and demonstrated to produce both symptomatic and imaging responses, saving vision in a
significant proportion;
 cranial radiotherapy to the visual pathways and hypothalamus was associated with significant cognitive and endocrine
morbidity that progressed through childhood and adolescence leading to lifelong disability;
 where chemotherapy was used, drug resistance did not seem to occur;
 drug selection was being driven by additional risks of hearing loss (cisplatin) in visually impaired children as well as long-
term risk of genotoxicity, particularly in NF1 associated cases
 tumour responses to chemotherapy were possible in about half of all patients, we had observed pseudo-progression at 12-
week assessments in our previous pilot trial;
 early true progression occurred in less than 30% and was predominantly associated with early age at onset (<1 year) in
patients with hypothalamic chiasmatic tumours, frequently associated with diencephalic syndrome and vision loss;
 late/sustained progression also occurred after stopping treatment, particularly in younger children with hypothalamic
chiasmatic tumours, sometimes justifying multiple lines of surgical and non-surgical therapy, including radiotherapy
 it was unresolved whether the tendency for tumours to recur/progress reduces as patients got older. Re-progression was
being observed during adolescence;
 the accepted age for consideration of radiotherapy over chemotherapy had risen from 5 years to older ages by the date of
launch of this trial;
 saving vision was an important target in the parents’ judgement at time of diagnosis and during treatment, influencing case
selection for non-surgical therapy;
 methods for vision assessment in children up to adolescence were complex with limited consensus across Europe. Direct
contact with vision specialists by those managing the chemotherapy varied considerably across the participating countries;
 methods for recording changes in neurological status linked to tumour effects were complex and remained in development;
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 A single randomised trial of two (vincristine and carboplatin) versus four drugs (thioguanine, procarbazine, CCNU and
vincristine) given over 12 months was in progress within the Children’s Oncology Group (COG) in USA. The VC arm and
the TPCV arm included three genotoxic drugs each respectively. The duration of therapy was 12 months.
Rationale for our trial
Given these circumstances and our experience of piloting the strategy for patient selection for observation or treatment after
primary surgery, and focussing on those with evidence, or at risk, of symptomatic progression, we decided to test whether
adding a third drug (etoposide), given at doses selected to limit genotoxicity, and not associated with known long term side-
effects, would improve response/non-progression rates, progression-free survival or overall survival. We selected 24 weeks as
the time to assess response/progression.
Added value of this study
This is the first multicentre, European and largest randomised trial worldwide investigating the role of chemotherapy in
children with LGG. The primary hypothesis that adding an additional drug to standard two-drug induction treatment would
improve response or non-progression rates was not supported.
As a result of this study we have identified that:
The eligibility criteria are acceptable and applicable for selecting patients with progressive disease and risk of symptomatic
progression as well defined criteria for study of patients recruited at diagnosis.
We can expect over 90% non-progression rate at 24weeks for newly diagnosed patients with progressive disease and those at risk
of symptomatic progression, offering reassuring evidence for the use of standardVCchemotherapy for newly diagnosedpatients.
Twenty-four-week response/progression assessment identified those with early progression and high risk of mortality
(52e54% mortality).
The relevance of proposed clinical risk factors, like young age, diencephalic syndrome, metastatic disease, specific histological
subtypes, is corroborated with previous reports.
Late or sustained progression remains a phenomenon with some patients requiring multiple lines of surgical and non-surgical
therapy.
Prolonged treatment for LGG is feasible, yet it remains to be shown whether it brings with itself a survival advantage. The
question of the optimal duration of treatment should be addressed. Toxicity of the vincristine/carboplatin (VC) regimen
remains significant;
The interaction between VC and etoposide, resulting in a reduced risk for carboplatin related hypersensitivity, is unexplained.
Risk of vision loss is a driver for consideration for therapy requiring enhanced consensus on methods of measuring risk of
vision loss across childhood.
The lack of strong evidence of the vision sparing qualities of this treatment in patients who are treated for vision threat alone
is a topic for future research which has already been initiated in NF1 associated LGG, and will influence the approach to
sporadic VPG, as a consensus on methods for vision assessment is now emerging.
Risk of neurological consequences for LGGs in different anatomical locations is predictable and methods for their mea-
surement and therefore correlation with tumour response and toxicity of therapies are now established and are being
incorporated into clinical trials platforms for the future.
Clinical conclusions
According to our present results, vincristine and carboplatin remains the standard treatment for newly diagnosed patients
with LGG with progressive disease or at risk of symptomatic disease in Europe. It of course needs further comparison with
other drug combinations.
Early evidence of progression by 24 weeks indicates a high mortality risk (justifying trial of new MAPKinase pathway
targeted drugs alone or in combination with existing chemotherapy agents, aimed at testing their effectiveness and toxicity).
Radiotherapy is increasingly being reserved for after second or third line chemotherapy in children who continue to progress
on chemotherapy.
Age <1 year at diagnosis, diencephalic syndrome and early progression are markers of risk of sustained progression and
higher mortality.
Treatment selections at such progressions should be driven by risk of symptomatic progression rather than imaging.
These patients present with complex problems affecting multiple systems justifying multidisciplinary team decision-making.
Increasing complexity may justify centralised decision systems nationally.
Research conclusions
Future studies of newly diagnosed patients for non-surgical therapy should be selected by standardised criteria for estimating
risk of symptomatic progression. Ideally, these criteria should be standardised internationally to enhance comparability of
results. We propose the SIOP LGG criteria as a candidate for such an international consensus.
Basic consideration for the design of a treatment of a new trial are:
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a) the high non-progression rates using VC,
b) the lack of evidence of additional benefit of an additional drug,
c) the high hypersensitivity rates for carboplatin and
c) the significant neurotoxicity of vincristine
We propose that:
 Future trials aim to identify less toxic and more effective treatments (especially with respect to visual function for visual
pathway glioma) in comparison to the standard VC combination. The new agents targeting the MAPKinase pathway are
likely to be candidates tested alone or in combination with existing chemotherapy agents. PFS, visual, neurological and
QoL measures should be considered for primary outcome in newly diagnosed cases in future trials.
 Those who progress by 24 weeks, despite chemotherapy, can also be considered for new MAPK targeted therapies that are
emerging from the current bioresearch agenda.
 Outcome criteria should include non-progression rates at 24 weeks, symptom response assessing vision and neurology and
measures of toxicity and tolerability, as well as PFS and OS.
 The optimal duration of therapy remains to be established overall and for different age groups.
 The explanation for sustained progression may be linked to ‘duration of therapy’ or ‘age at discontinuation of therapy’, if
age is a proxy for factors linked to brain growth in different anatomical regions.
 Trials designed to assess both ‘duration of therapy hypothesis’ and ‘age at finishing treatment hypothesis’ are candidates for
future research.
 Elucidating the mechanism of etoposide modification of carboplatin hypersensitivity may offer a mechanism for managing
this consequence of prolonged carboplatin exposure in the future.
Those who progress by 24 weeks, despite chemotherapy, can also be considered for new MAPK targeted therapies that are
emerging from the current bioresearch agenda.
Outcome criteria should include non-progression rates at 24 weeks, symptom response assessing vision and neurology and
measures of toxicity and tolerability, as well as PFS and OS.
The optimal duration of therapy remains to be established overall and for different age groups.
The explanation for sustained progression may be linked to ‘duration of therapy’ or ‘age at discontinuation of therapy’, if age
is a proxy for factors linked to brain growth in different anatomical regions.
Trials designed to assess both ‘duration of therapy hypothesis’ and ‘age at finishing treatment hypothesis’ are candidates for
future research.
Elucidating the mechanism of etoposide modification of carboplatin hypersensitivity may offer a mechanism for managing
this consequence of prolonged carboplatin exposure in the future.
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new treatments to be tested as they are at greatest risk of
suffering neurological and endocrine damage and are at
high risk of death. The >8-year-old group needs further
study to understand the interactions between age, pu-
bertal development, histology and sensitivity to
chemotherapy.
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